# Marizomib Central Nervous System (CNS)

> **NCT05050305** · PHASE2 · WITHDRAWN · sponsor: **Dana-Farber Cancer Institute**

## Conditions studied

- Multiple Myeloma
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory

## Interventions

- **DRUG:** Marizomib
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05050305
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-03
- **Primary completion:** 2025-12
- **Final completion:** 2027-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study support withdrawn
- **Last updated:** 2024-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05050305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05050305, "Marizomib Central Nervous System (CNS)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05050305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*